Welcome to our dedicated page for Intelligent Bio Solutions news (Ticker: INBS), a resource for investors and traders seeking the latest updates and insights on Intelligent Bio Solutions stock.
Intelligent Bio Solutions Inc. (INBS) is a progressive life sciences company committed to enhancing health care through innovative non-invasive diagnostic tests. The company's primary focus lies in developing real-time monitoring solutions that aid patients and health practitioners in managing chronic diseases efficiently. Through its cutting-edge Biosensor Platform, Intelligent Bio Solutions Inc. is pioneering diagnostic tests that are urgently required to improve patient outcomes and streamline medical diagnostics.
One of the company's significant advancements is in the realm of portable drug abuse testing. Utilizing fingerprint sweat analysis, INBS offers a non-invasive, hygienic, and rapid drug screening solution. This technology is engineered to detect the recent use of substances such as opioids, cocaine, methamphetamines, benzodiazepines, and marijuana, making it an invaluable tool in both clinical and legal settings.
Intelligent Bio Solutions Inc. has demonstrated substantial growth and success, as evidenced by an impressive year-over-year unaudited revenue increase of 80% for the fiscal third quarter and 193% for the nine months ending March 31, 2024. The company also reported its highest quarterly cartridge sales since acquiring Intelligent Fingerprinting in 2022, highlighting the growing demand and effectiveness of its products.
For more information, visit: http://www.ibs.inc/.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) has announced its collaboration with Dodman Limited, a UK manufacturer, to implement the Intelligent Fingerprinting Drug Screening System for workplace drug testing. This system offers a non-invasive alternative to traditional urine tests by analyzing fingerprint sweat samples. It enables quick on-site testing, yielding results in under ten minutes. Dodman aims to enhance its health and safety reputation by proactively introducing random drug testing across its operations.
Dodman's Health and Safety Manager, Chris Davies, emphasized the benefits of this approach, noting improved safety and differentiation in the market. Intelligent Bio Solutions recognizes the increasing importance of drug testing for employee safety and offers an innovative solution that is both efficient and accurate.
Intelligent Bio Solutions Inc. (Nasdaq: INBS) has been granted its 13th patent in the UK for its Intelligent Fingerprinting Drug Screening System DSR-Plus Cartridge Reader. This patent enhances the protection of the company’s proprietary drug screening technology, focusing on its lateral flow test strip reading capability. The DSR-Plus reader enables fast and accurate drug testing using fingerprint sweat analysis, with results in under ten minutes. The portable unit is designed for resilience and improved battery life, making it suitable for various organizations. The technology aims to help employers deter workplace drug abuse, with applications in safety-critical industries including construction and logistics. CEO Harry Simeonidis highlighted the patent's importance in expanding their international business and strengthening their intellectual property portfolio.
FAQ
What is the current stock price of Intelligent Bio Solutions (INBS)?
What is the market cap of Intelligent Bio Solutions (INBS)?
What does Intelligent Bio Solutions Inc. specialize in?
What is the Biosensor Platform?
How does INBS's drug abuse testing technology work?
What recent financial achievements has Intelligent Bio Solutions Inc. reported?
When did INBS achieve its highest quarterly cartridge sales?
Who are the primary contacts for Intelligent Bio Solutions Inc.?
Where can I find more information about the company?
What chronic diseases does INBS focus on with its diagnostic tests?
What substances can INBS's drug screening test detect?
How does the fingerprint sweat analysis benefit users?
